(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Zelensky names spy chief to head presidential office after corruption row - 2Brazil's agricultural research agency gets cannabis research greenlight
- 3No respite for German economy as experts slash forecast over Iran war
- 4Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- 5How mountain terraces have helped Indigenous peoples live with climate uncertainty
- Artemis II astronauts make long-distance call to the space station as they head home from the moon
- How to watch 'A Charlie Brown Christmas' for free this weekend
- A Manual for Extravagant Vehicles Available in 2024
- US FDA approves Kura-Kyowa's blood cancer therapy
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- 6 Robot Vacuum Cleaners for Easy Home Cleaning
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
